The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of North Carolina at Chapel Hill

University of Kansas

R Benjamin Free

Noel Terrence Southall

Marc Ferrer

David Robert Sibley

Xin Hu

Kevin Frankowski

Warren S Weiner

Joseph Perry Steiner

Jeffrey Aubé

Amy Elizabeth Moritz

Juan Jose Marugan

Jingbo Xiao

Prashi Jain

Jennie L Conroy

Kathryn D Luderman

Jeffrey AubÉ

The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof

Selective D3 dopamine receptor agonists and methods of their use

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

Selective Ddopamine receptor agonists and methods of their use

The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine Dreceptor. The variables R-R, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia. 

11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists

Growing community of inventors

Bethesda, MD, United States of America

R Benjamin Free